Eisai Company, Limited

Sansho Co., Ltd.

Masanori Kayano

Sumio Watanabe

Masayoshi Kasai

Keizo Uesugi

Yoshio Ishino

Yasuhiko Mizuno

Yoshio Tanabe

Yasuo Ishibashi

Mitsuhiro Yoshida

Masahiro Kawahara

Katsumi Ida

Shigeru Sakashita

Ryoichi Machida

Hiroyuki Fujimori

Shigeru Aoki

Shigemitsu Osawa

Toji Konishi

Takayuki Ikeuchi

Nobutaka Noda

Isamu Hasegawa

Michiru Tanaka

Kohei Miyao

Satoshi Yamagiwa

Yoshio Taguchi

Toshio Kurobe

Hidenori Asakawa

A polyprenyl compound having formula (1) is stabilized by a tocopherol, an organic acid, a neutral amino acid or a basic amino acid: ##STR1## in which n is an integer of 1 to 3.

Stabilization of polyprenyl compound

A preparation containing a cephalosporin medicament is disclosed. The preparation comprises a cephalosporin derivative represented by the following formula: ##STR1## namely, 7.beta.-{2-(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-2-fluoromethoxyiminoacetami do}-3-{(E)-3-(carbamoylmethylethylmethylammonio) -1-propen-1-yl}-3-cephem-4-carboxylate or a pharmaceutically acceptable salt thereof salt, lactose, citric acid or a sodium salt thereof, and arginine or a hydrochloride thereof; or the cephalosporin derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof, lactose, citric acid or a sodium salt thereof, and sodium chloride.

Injectable preparations containing cephalosporin medicament

A pharmacological composition for soft capsules, containing a polyprenyl compound having the formula (1) and a surfactant and/or an unsaturated aliphatic acid, has improved absorbability. ##STR1## wherein n represents 1 to 3.

Polyprenyl compound composition for soft capsules

A pharmaceutical composition comprises (a) a pharmacologically effective amount of bunazosin or a pharmacologically acceptable salt thereof and (b) a monoglyceride of a fatty acid having 8 to 12 carbon atoms and/or a lactic acid ester of an aliphatic alcohol having 12 to 18 carbon atoms and is improved in percutaneous administration. ##STR1##

Pharmaceutical preparation for percutaneous administration containing

An aqueous solution containing fat-soluble vitamin K is prepared by adding vegetable oil(s), gycerol fatty acid ester(s) or sorbitan fatty acid ester(s) in an amount of 0.004 to 5% by weight, based on the whole aqueous solution, to an aqueous solution containing menatetrenone (vitamin K.sub.2) or phytonadione (vitamin K.sub.1) and hydrogenated lecithin.

Aqueous solution containing fat-soluble vitamin K

A multi-layered granule comprises an inner, slow-releasing layer, an outer, rapid-releasing layer and an intermediate layer provided between said slow-releasing layer and said rapid-releasing layer which intermediate layer comprises a hardened oil and hydroxypropyl cellulose or methyl cellulose.

Multi-layer granule

An effervescent vaginal suppository composition containing a stabilizer appropriately selected from the group consisting of anhydrous sodium sulfate, anhydrous silica gel, dried magnesium silicate, dried aluminum silicate, dried calcium carboxymethylcellulose, dried microcrystalline cellulose, dried starch and dried calcium phosphate or mixtures thereof, preferably in an amount of 0.1-20% based on the weight of said effervescent vaginal suppository composition. Shaped effervescent vaginal suppositories are produced therefrom.

Stable, effervescent vaginal suppositories

A sugar-coated tablet for medical use comprising a core containing low-melting fat-soluble pharmaceutical material and a sugar coating layer on said core, which is characterized by the feature that at least one water-soluble cellulose ether coating film is present between the core and the sugar-coating layer.

Sugar-coated tablet containing fat-soluble pharmaceutical material

A soft-gelatin capsule having a coating film layer of carnauba wax on the outer surface of the soft-gelatin shell. Preferably, the amount of the carnauba wax is at least 0.002 part by weight based on 100 parts by weight of the amount of the soft-gelatin shell.

Soft capsule coated with a film of carnauba wax and process for the

A hollow particulate for gastric medicines and other durable medicines suspendable in the gastric juice and remainable in the stomach for a long period of time is provided which has been prepared by dissolving ethylcellulose in a lower chlorinated hydrocarbon, or a mixed solution of the lower chlorinated hydrocarbon and a lower chlorofluorinated hydrocarbon and/or water, so that the concentration of ethylcellulose is 0.5 - 4% by weight on the basis of the total weight of the resulting solution, and then spray-drying the solution at an inlet temperature of higher than 50.degree. C.

Process for the preparation of hollow particulates

A solid therapeutic preparation for gastric diseases, remaining in stomach for a long period of time and gradually releasing pharmacologically active ingredient contained therein into gastric juice while remaining in stomach, is provided which has been prepared by impregnation of the active ingredient together with other suitable additives into a body of empty globular shell or a granular lump in small size of the material having high buoyancy. The persisting effect of the active ingredient in stomach is thus attained.

Solid therapeutic preparation remaining in stomach

Warm-blooded animals having hyperammoniemia are treating by administration of a pharmaceutical composition comprising nicotinohydroxamic acid.

Growing community of inventors

Saitama, Japan

Masanori Kayano